1-2 of 2
CoOperative Study Group A for Hematology (COSAH)
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparable Allogeneic Hematopoietic Cell Transplantation Outcome of a Haplo-Identical Family Donor with an Alternative Donor in Adult Aplastic Anemia

Subject Area:
Hematology , Oncology
Hawk Kim, Je-Hwan Lee, Young-Don Joo, Sung-Hwa Bae, Sang Min Lee, Jae-Cheol Jo, Yunsuk Choi, Jung-Hee Lee, Dae-Young Kim, Hun Mo Ryoo, Kyoo-Hyung Lee, CoOperative Study Group A for Hematology (COSAH)
Journal: Acta Haematologica
Acta Haematol (2016) 136 (3): 129–139.
https://doi.org/10.1159/000445820
Published Online: 14 July 2016
View articletitled, Comparable Allogeneic Hematopoietic Cell Transplantation Outcome of a Haplo-Identical Family Donor with an Alternative Donor in Adult Aplastic Anemia
Open the PDF for Comparable Allogeneic Hematopoietic Cell Transplantation Outcome of a Haplo-Identical Family Donor with an Alternative Donor in Adult Aplastic Anemia in another window
Journal Articles

Prospective, Multicenter, Phase II Study on Reducing the Dosage of Idarubicin and FLAG for Patients Younger than 65 Years with Resistant Acute Myeloid Leukemia: A Comparison with a Higher Dosage Trial

Subject Area:
Hematology , Oncology
Hawk Kim, Je-Hwan Lee, Young-Don Joo, Sung Hwa Bae, Jung-Hee Lee, Dae-Young Kim, Won-Sik Lee, Hun-Mo Ryoo, Jae-Cheol Jo, Jae-Hoo Park, Kyoo-Hyung Lee, and CoOperative Study Group A for Hematology (COSAH)
Journal: Acta Haematologica
Acta Haematol (2014) 132 (1): 87–96.
https://doi.org/10.1159/000357093
Published Online: 07 February 2014
View articletitled, Prospective, Multicenter, Phase II Study on Reducing the Dosage of Idarubicin and FLAG for Patients Younger than 65 Years with Resistant Acute Myeloid Leukemia: A Comparison with a Higher Dosage Trial
Open the PDF for Prospective, Multicenter, Phase II Study on Reducing the Dosage of Idarubicin and FLAG for Patients Younger than 65 Years with Resistant Acute Myeloid Leukemia: A Comparison with a Higher Dosage Trial in another window